Medias Klinikum
Hospital
Location:
Burghausen,
Germany (DE)
ISNI: -
ROR: https://ror.org/05kvypp26
LOOSING DAS28-ESR, BUT STAYING IN BOOLEAN REMISSION-IS IT POSSIBLE? DATA FROM THE PROSPECTIVE, RANDOMISED RETRO TRIAL ON RHEUMATOID ARTHRITIS PATIENTS IN STABLE REMISSION (2018)
Erhard J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al.
Conference contribution
ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY (2017)
Rech J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al.
Conference contribution
MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION (2017)
Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al.
Conference contribution
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs (2017)
Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber A, Haschka J, Manger B, et al.
Journal article
ANTI-MODIFIED PROTEIN ANTIBODY RESPONSE PATTERN INFLUENCES THE RISK FOR DISEASE RELAPSE IN RHEUMATOID ARTHRITIS PATIENTS TAPERING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (2016)
Figueiredo C, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, et al.
Conference contribution
EFFECTS OF DMARD TAPERING ON TREATMENT COSTS IN RHEUMATOID ARTHRITIS PATIENTS-AN ANALYSIS FROM THE PROSPECTIVE RANDOMIZED CONTROLLED RETROSTUDY (2016)
Hagen M, Figueiredo C, Cobra JF, Reiser M, Haschka J, Englbrecht M, Hueber A, et al.
Conference contribution
RETRO - STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION (2015)
Haschka J, Englbrecht M, Hueber A, Manger B, Kleyer A, Reiser M, Finzel S, et al.
Conference contribution